NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Lisata Therapeutics, Inc. LSTA
16 fiscal years on record · USD · FY2025 reported · SEC filings only
Growth
USD 170,000.00
Revenue, FY2025 · full 16-year series below
Revenue $M
Net income $M
FY2025 · Revenue 0.2 · Net income -16.6
Compound annual growth
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
−9756 cents
lost on every revenue dollar
Operating margin
Net margin
FY2025 · Operating -10711.2% · Net -9756.5%
ROE
FY2025 · ROE -74.7%
Each USD of equity lost 75 cents this year.
The 16-year record
16 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | 0.0 | · | · | · | · | · | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 |
| Operating income $B | −0.0 | −0.0 | −0.0 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 |
| EBITDA $B | −0.0 | −0.0 | −0.0 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 | · |
| Income tax $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | 0.0 | 0.0 | −0.0 | 0.0 | −0.0 | −0.0 | 0.0 | −0.0 | 0.0 | 0.0 |
| Net income $B | −0.0 | −0.0 | −0.0 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | 0.0 | −0.0 | −0.1 | −0.1 | −0.0 | −0.1 | −0.0 | −0.0 |
| Free cash flow $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 |
| EPS, diluted $ | −1.91 | −2.40 | −2.58 | −10.47 | −7.45 | −0.53 | −1.88 | −1.67 | 2.56 | −4.99 | −16.67 | −1.68 | −1.90 | −4.00 | −0.54 | −0.46 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | −0 | −0 | −1 | −0 | −1 |
| ROE % | −74.7 | −51.4 | −36.3 | −68.3 | −44.0 | −30.6 | −66.1 | −36.6 | 83.0 | −228.4 | · | −90.7 | −81.4 | −113.0 | −85.2 | −47.9 |
| Shares out B | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.04 | 0.03 | 0.02 | 0.11 | 0.06 |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 62 reconciliationsAUDITED
Reconciled in 16 of 19 fiscal years. 30 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2010